Holen Sie sich die Stockscreener-App
165.35
0.20%
-0.33
Handel nachbörslich:
165.35
Schlusskurs vom Vortag:
$165.68
Offen:
$164.57
24-Stunden-Volumen:
1.12M
Relative Volume:
0.72
Marktkapitalisierung:
$11.45B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$302.80M
KGV:
38.48
EPS:
4.2965
Netto-Cashflow:
$387.80M
1W Leistung:
+1.28%
1M Leistung:
+8.60%
6M Leistung:
-35.36%
1J Leistung:
-42.67%
1-Tages-Spanne:
$162.43
$168.36
1-Wochen-Bereich:
$161.62
$172.91
52-Wochen-Spanne:
$138.79
$354.88
Insulet Corp Stock (PODD) Company Profile
Firmenname
Insulet Corp
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
165.35 | 11.43B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corp Aktie (PODD) Neueste Nachrichten
PODD SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Insulet Corporation Investors - GlobeNewswire Inc.
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Corp (PODD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insulet Corp (PODD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Insulet Market Sentiment - Benzinga España
Insulet Corp (PODD) Income Statement - TradingKey
PODD|Insulet Corp|Price:164.940|Chg%:+1.680 - TradingKey
Insulet Corp (PODD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Insulet Corp (PODD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD - GlobeNewswire Inc.
Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh - TradingView
Insulet Corp (PODD) Cash Flow - TradingKey
Insulet Corp (PODD) Shares Surge 3.1% -- What GF Score of 81 Tel - GuruFocus
Insulet examines mental health toll of diabetes in partnership with meditation app Calm - Medical Marketing and Media
Insulet Corp (PODD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain OfficersPODD - PR Newswire
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corporation (PODD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insulet's Q2 2026 Earnings: What to Expect - Yahoo Finance
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Insulet Corporation Class Action Reminder – Robbins LLP - GlobeNewswire
Insulet stock trades steady as Omnipod growth supports long term diabetes opportunity - Ad-hoc-news.de
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Planet Fitness, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
PODD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation - GlobeNewswire
Lost Money on Insulet Corporation (PODD)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - GlobeNewswire
PODD SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - marketscreener.com
Robbins LLP Urges PODD Stockholders to Contact the Firm for Information About the Class Action Against Insulet Corporation - TMX Newsfile
PODD DEADLINE: The Gross Law Firm Reminds Insulet - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Insulet stock trades near recent lows as Omnipod margins tighten after GLP-1 demand shift - Ad Hoc News
Insulet Corp (PODD) Stock Up 3.2% and Still Undervalued -- GF Sc - GuruFocus
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum - ChartMill
Lila Moss narrates a new sleep story for the diabetes community - Stock Titan
INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Insulet Investors of - The National Law Review
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
PODD Court News: Insulet Class Action Lawsuit Alleges Securities Fraud on behalf of Investors with Losses - PR Newswire
Insulet Corporation (PODD) Fell Along with Broad Medtech Sector - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago - Yahoo Finance
Lobbying Update: $60,000 of INSULET CORPORATION lobbying was just disclosed - Quiver Quantitative
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Insulet - GlobeNewswire
PODD Shareholder Alert: Insulet Corporation Securities - GlobeNewswire
Stifel cuts Insulet stock price target on valuation, keeps buy rating - Investing.com
Insulet stock reflects steady diabetes tech demand as investors watch U.S. growth - AD HOC NEWS
Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47% - Yahoo Finance
Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap? - Yahoo Finance
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation LawsuitPODD - Morningstar
PODD Shareholder Alert: Insulet Corporation Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Finanzdaten der Insulet Corp-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insulet Corp-Aktie (PODD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BORIO LUCIANA | Director |
Jun 03 '26 |
Sale |
143.27 |
418 |
59,887 |
4,329 |
| WEATHERMAN ELIZABETH H | Director |
Jun 03 '26 |
Buy |
144.20 |
3,450 |
497,490 |
10,352 |
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):